Jeffrey A. Gray and Neil McNaughton
- Published in print:
- 2003
- Published Online:
- January 2008
- ISBN:
- 9780198522713
- eISBN:
- 9780191712517
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780198522713.003.0004
- Subject:
- Psychology, Neuropsychology
This chapter defines anti-anxiety (anxiolytic) drugs, and reviews their types, clinical use, and behavioural pharmacology. Classical anxiolytic drugs and novel anxiolytic drugs share only anxiolytic ...
More
This chapter defines anti-anxiety (anxiolytic) drugs, and reviews their types, clinical use, and behavioural pharmacology. Classical anxiolytic drugs and novel anxiolytic drugs share only anxiolytic action and no side-effects, in the clinic. They also share common actions on behaviours attributable to the behavioural inhibition system by the analysis of Chapter 3. Specific details of the changes produced lead to the conclusion that these drugs do not affect behaviours as such but rather, in other species as well as humans, act fundamentally to reduce anxiety itself.Less
This chapter defines anti-anxiety (anxiolytic) drugs, and reviews their types, clinical use, and behavioural pharmacology. Classical anxiolytic drugs and novel anxiolytic drugs share only anxiolytic action and no side-effects, in the clinic. They also share common actions on behaviours attributable to the behavioural inhibition system by the analysis of Chapter 3. Specific details of the changes produced lead to the conclusion that these drugs do not affect behaviours as such but rather, in other species as well as humans, act fundamentally to reduce anxiety itself.
Donald S. Robinson
- Published in print:
- 1991
- Published Online:
- March 2012
- ISBN:
- 9780192620118
- eISBN:
- 9780191724725
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780192620118.003.0013
- Subject:
- Neuroscience, Techniques
Buspirone's initial clinical development involved treatment of chronic anxiety in patients generally corresponding to the DSM-III. Dysfunction of central serotonergic neuronal systems is implicated ...
More
Buspirone's initial clinical development involved treatment of chronic anxiety in patients generally corresponding to the DSM-III. Dysfunction of central serotonergic neuronal systems is implicated in mood disorders, and treatment of these disorders has recently been focused on this neurotransmitter. The 5-HT1A partial agonists possess a pharmacological profile predictive of both antidepressant and anxiolytic activity. Placebo-controlled studies with buspirone and gepirone in depressive disorders have shown that these agents produce significant therapeutic benefit. Buspirone and gepirone treatment resulted in global improvement of depressed patients, and specifically benefited symptoms of depressed mood, work and activity, anergia, diurnal variation, and other cardinal symptoms of depression.Less
Buspirone's initial clinical development involved treatment of chronic anxiety in patients generally corresponding to the DSM-III. Dysfunction of central serotonergic neuronal systems is implicated in mood disorders, and treatment of these disorders has recently been focused on this neurotransmitter. The 5-HT1A partial agonists possess a pharmacological profile predictive of both antidepressant and anxiolytic activity. Placebo-controlled studies with buspirone and gepirone in depressive disorders have shown that these agents produce significant therapeutic benefit. Buspirone and gepirone treatment resulted in global improvement of depressed patients, and specifically benefited symptoms of depressed mood, work and activity, anergia, diurnal variation, and other cardinal symptoms of depression.
